TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25495719
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg daily for 12 weeks
Study: 25495719
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg daily for 12 weeks
Study: 20082737
Drug: High-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol cocoa beverage (701 mg)
Study: 20082737
Drug: Low-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol cocoa beverage (22 mg)
Study: 19057628
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of 6 mg non‐particulate Celestone
Study: 19057628
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections (both groups)
Study: 10897159
Drug: LEV 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 3,000 mg
Study: 8604240
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (10 mg/m2), and fluorouracil (500 mg/m2; CNF)
Study: 1420740
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine administered at bedtime
Study: 1420740
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine administered post evening meal
Study: 29882843
Drug: WBE111 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBE111 (100 mg)
Study: 27418883
Drug: BCAA (0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (0.17 g/kg), arginine (0.05 g/kg), citrulline (0.05 g/kg)
Study: 20979906
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg by muscle injection
Study: 20979906
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline 2 ml
Study: 18783360
Drug: Interventional pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional pain therapies
Study: 12147929
Drug: ACE inhibitor/HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor/HCTZ combinations
Study: 10358862
Drug: Diovan (valsartan)
Normalized name: valsartan Oral Tablet [Diovan]
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diovan (valsartan) 80 mg/day for 8 weeks, increased to 160 mg/day if needed
Study: 1782973
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 100 mg
Study: 1782973
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 100 mg with quinidine sulphate 50 mg pretreatment
Study: 1782973
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 100 mg in PM
Study: 1782973
Drug: Quinidine sulphate
Normalized name: Quinidine sulphate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulphate 50 mg
Study: 938185
Drug: Drug alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug alone
Study: 6113821
Drug: Psychotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy plus drug
Study: 23715753
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 200 units/mL once daily
Study: 23715753
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL once daily
Study: 19270299
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) with community-based promotional activities
Study: 19270299
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) without community-based promotional activities
Study: 19270299
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) during low transmission season
Study: 15516639
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral iron supplementation (2 mg/kg/day)
Study: 11226441
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 100 microg, repeated once after 6 h if not in active labor
Study: 11226441
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two doses of vitamin C after a 6-h interval)
Study: 2663518
Drug: Tobramycin in
Normalized name: tobramycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin in combination with ampicillin
Study: 2663518
Drug: Ceftazidime in
Normalized name: ceftazidime Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime in combination with ampicillin
Study: 31254718
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (0.6 mg/kg/h)
Study: 28409508
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg.kg-1 30 minutes before tests)
Study: 27966504
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) as an adjunct to scaling and root planing (SRP)
Study: 22870302
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride solution (5%)
Study: 22870302
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride solution (1% or 2%)
Study: 18808624
Drug: Si‐Wu‐Tang (SWT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Si‐Wu‐Tang (SWT) 15 g daily for seven consecutive days after cessation of menstrual bleeding
Study: 18808624
Drug: Si‐Wu‐Tang (SWT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Si‐Wu‐Tang (SWT) 15 g daily as soon as menstrual bleeding is noted
Study: 9058001
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (various other therapies including speech therapy and occupational therapy)
Study: 2887186
Drug: Metoprolol (243
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (243 +/- 26 mg daily)
Study: 2887186
Drug: Propranolol (149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (149 +/- 16 mg daily)
Study: 2887186
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 +/- 8 mg daily)
Study: 2919849
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (10 mg)
Study: 2919849
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (20 mg)
Study: 28465224
Drug: Shoe orthotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoe orthotics plus chiropractic treatment
Study: 28465224
Drug: Waitlist group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist group (no treatment)
Study: 23114033
Drug: Fluoride followed
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride followed by laser treatment
Study: 19537524
Drug: DoloVisano Methocarbamol
Normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DoloVisano Methocarbamol 750 mg (test product)
Study: 15515038
Drug: 20 min
Normalized name: wheat germ oil 20 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min daily exposure to static magnetic fields (4 patients)
Study: 15515038
Drug: 70 min
Normalized name: TITANIUM DIOXIDE 44.26 mg in 1 mL / ZINC OXIDE 50.3 mg in 1 mL TOPICAL LOTION [Australian Gold Botanicals Sunscreen 70 Minerals]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 min daily exposure to static magnetic fields (7 patients)
Study: 9335514
Drug: Taxoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxoid therapy (combination with various chemotherapeutic agents and monoclonal antibodies)
Study: 9335514
Drug: Taxoid monotherapy
Normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxoid monotherapy or combination therapy
Study: 2906873
Drug: Ramixotidine 750
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramixotidine 750 mg (CM 57755A)
Study: 28502786
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Graded Exercise Therapy (GET) for 12 weeks
Study: 18320559
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for 6 weeks
Study: 12904191
Drug: Group L10F25
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L10F25 (10 mg lidocaine plus 25 microg fentanyl)
Study: 12904191
Drug: Group L10F25E15
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L10F25E15 (10 mg lidocaine plus 25 microg fentanyl plus 15 microg epinephrine)
Study: 12904191
Drug: Group L20F25
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L20F25 (20 mg lidocaine plus 25 microg fentanyl)
Study: 9049593
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata gum resin (350 mg thrice daily for 6 weeks)
Study: 9049593
Drug: Sulfasalazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (1 g thrice daily)
Study: 3519694
Drug: Isocarboxazid (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocarboxazid (50 mg)
Study: 30557404
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (1,000 IU/day) and Calcium (1,200 mg/day)
Study: 28475205
Drug: Systemic ELF‐MF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic ELF‐MF therapy (100 microtesla, 1 to 80 Hz)
Study: 28475205
Drug: ELF‐MF therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELF‐MF therapy
Study: 23812596
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (Zol) 5 mg intravenous once yearly
Study: 22490477
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 100 mg intravenously 15 minutes before incision (PA group)
Study: 21284135
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion monotherapy (switching strategy)
Study: 21284135
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion plus citalopram (combination strategy)
Study: 12213507
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) treatment programme for 12 weeks
Study: 20184287
Drug: Emoxipine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipine (150 mg, i.v., daily) for 14 days
Study: 20184287
Drug: Reamberin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (400 ml, i.v., daily) for 14 days
Study: 20184287
Drug: Mexidol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (300 mg, i.v., daily) for 14 days
Study: 16142873
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg subcutaneous injection twice weekly for 24 weeks
Study: 10440621
Drug: Single-dose sparfloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sparfloxacin (400 mg on day 1)
Study: 10440621
Drug: 3-day sparfloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day sparfloxacin (400 mg loading dose on day 1 followed by 200 mg once daily for 2 additional days)
Study: 10440621
Drug: 7-day ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day ciprofloxacin (250 mg twice daily for 7 days)
Study: 1495785
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg 5 times daily) for 7 days
Study: 1495785
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg 5 times daily) for 14 days
Study: 6496206
Drug: Reactive condition
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive condition (telephone contact by an assistant in the original smoking cessation treatment program)
Study: 27084538
Drug: Oral elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral elemental diet (ED) - 300 kcal of ED plus regular diet for 6-8 weeks after surgery
Study: 27084538
Drug: Oral elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral elemental diet (ED) - in total gastrectomy patients
Study: 23710734
Drug: Boceprevir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir plus peginterferon alfa-2b/ribavirin (triple therapy)
Study: 23710734
Drug: Boceprevir (t.d.s.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir (t.d.s. dosing interval 7-9 h)
Study: 7796899
Drug: The pill
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pill
Study: 2084879
Drug: Nicardipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (40 or 60 mg)
Study: 2084879
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 or 30 mg)
Study: 25361222
Drug: Ghrelin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (0.5 μg/kg/h) for 5 days
Study: 21161666
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (CHOc)
Study: 21161666
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (CHO)
Study: 19241334
Drug: Rowatinex, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowatinex, 100 mg, 3 times per day
Study: 15291124
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg tid for 4 days
Study: 11304896
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dose of atrasentan
Study: 11304896
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of atrasentan
Study: 11304896
Drug: 23.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.25 mg dose of atrasentan
Study: 11304896
Drug: 139.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 139.5 mg dose of atrasentan
Study: 11304896
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of atrasentan
Study: 9385283
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin (200 IU daily for 28 days)
Study: 9113120
Drug: Tropisetron (Navoban)
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (Navoban) monotherapy
Study: 9113120
Drug: All antiemetic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antiemetic treatments
Study: 347574
Drug: Apomorphine (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (subcutaneous doses)
Study: 31918760
Drug: Transdiagnostic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic treatment protocol using an adapted version of the Problem Management Plus (PM+) protocol, consisting of six 90-min sessions.
Study: 30753642
Drug: Vaginal tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal tenofovir (TFV) 1% gel
Study: 28271493
Drug: Orbis' microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbis' microsphere prednisone formulation
Study: 28271493
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Roxanne Laboratories)
Study: 26095784
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg) every 2 weeks
Study: 21975231
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no stem cell treatment)
Study: 16899031
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) or Placebo
Study: 15205853
Drug: 7.2 mM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2 mM sodium nitroprusside (SNP) solution (2.16 mg/ml)
Study: 11348560
Drug: Spray-dried antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-dried antioxidant supplement (30 g) for 2 weeks
Study: 9421873
Drug: Bayesian solution
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian solution using BUGS implementation of Gibbs sampling
Study: 9421873
Drug: Naive analyses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naive analyses using average risk in control and treatment groups
Study: 3540836
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar volume of drug vehicle)
Study: 27523436
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of resveratrol/day for 4 weeks
Study: 12840088
Drug: CAF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF plus high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation
Study: 12840088
Drug: CAF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF plus high-dose chemotherapy and stem-cell transplantation
Study: 10821295
Drug: Rosiglitazone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 12 mg
Study: 8690280
Drug: Octreotide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.6 mg/24 hr)
Study: 30418492
Drug: Adaptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive treatment designs and Sequential Multiple Assignment Randomized Trial
Study: 9524970
Drug: Antibiotic susceptibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic susceptibility
Study: 8475837
Drug: Postoperative subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subconjunctival 5-fluorouracil (5-FU) injections
Study: 21837
Drug: Ca-containing antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-containing antacid
Study: 21837
Drug: Ca-free antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-free antacid
Study: 31896620
Drug: Omaveloxolone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaveloxolone 160 mg
Study: 31623400
Drug: L-theanine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (200 mg/day)
Study: 28748995
Drug: Mindfulness intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness intervention (8 weekly 45-minute sessions)
Study: 31000508
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 2.5 mg dexamethasone
Study: 31000508
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dexamethasone injection)
Study: 25590358
Drug: Griffonia simplicifolia/magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griffonia simplicifolia/magnesium complex (50 and 200 mg, respectively), orally administered twice a day for 3 months
Study: 25590358
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy for MS
Study: 22029641
Drug: short‐acting MPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: short‐acting MPH (0.5 mg/kg)
Study: 16981274
Drug: Weiansan (WAS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weiansan (WAS) 5 g, 3 times a day
Study: 16981274
Drug: Weifuchun (WFC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weifuchun (WFC) 4 tablets, 3 times a day
Study: 16981274
Drug: High-dose WAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose WAS
Study: 16981274
Drug: Low-dose WAS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose WAS
Study: 27503640
Drug: EDP-239 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-239 (100 mg single dose)
Study: 25436815
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin supplementation (B complex, C, and E)
Study: 23108516
Drug: Amoxicillin 3
Normalized name: amoxicillin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3 g orally
Study: 23108516
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg orally
Study: 19850639
Drug: CTC detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC detection before chemotherapy